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A new series of novel 1-benzoyl-4-(4-aroyl/aroyloxy methyl)-3-methyl-6-oxo-6,7-dihydro-1H-pyrazolo [3,4-b] pyridine-
5-carbonitrile have been synthesized from a common intermediate, in good yields. These compounds have been screened for 
their antibacterial and antifungal activity against different pathogenic strains of bacteria and fungi. The minimum inhibitory 
concentration (MBC) and minimum fungicidal concentration (MFC) have been determined for the test compounds as well as 
for reference standards. Compounds 3c, 3f, 3h, 3i, 3n, 3o, 3p have shown good antibacterial activity where as compounds 
3b, 3e, 3g, 3i, 3p have displayed better antifungal activity. 
Keywords: Substituted aroyl/aroyloxymethyl, Schiff base, pyrazolin, pyridine, carbonitrile, antimicrobial, antibacterial 
activity, antifungal activity 
Efficient synthesis of drug-like small molecules has 
been the focus of the research for medicinal chemists 
and chemical biologists because they play a very 
important role in drug discovery processes1. These 
different drug-like bioactive compounds are broadly 
used to modulate enzyme or receptor function and can 
serve as important leads for drug development2-4. 
Pyrazoles represent a key structural motif in 
heterocyclic chemistry and occupy a significant 
position in medicinal and pesticide chemistry because 
of their capability to exhibit a wide range of 
biological activities including antibacterial5-8, 
antifungal9, antidiabetic10 herbicidal11, analgecic12, 
antitumor13, anti-anxiety14 and antihyperglycemic 
activity15. The use of pyrazole derivative as potential 
antimicrobial agents has received considerable 
attention following the discovery of the natural 
pyrazole C-glycoside, pyrazofurin that demonstrated a 
broad spectrum of antimicrobial activity16. Prazolo 
[3,4-b] pyridine skeleton have proven to be interesting 
classes of heterocycles due to diverse biological 
properties including antitubercular, antibacterial and 
antioxidant activities17-19. Recently, many authors20 
synthesized pyrazolo [3,4-b] pyridine by novel 
methods. J Quiroga and coworkers21,22 have been 
prepared pyrazolo [3,4-b] pyridine by the reaction of 
5-amino-3-methyl/phenyl-1-phenyl/H-1H-pyrazole 
and chalcones of benzoyl acetonitrile/malononitrile 
with some aromatic aldehydes. The cyano group is a 
stable and useful functional group that can be 
transformed to various other functional groups such as 
acyl, carboxy, formyl, carbamoyl, etc.23 The past 
seven decades has witnessed the transition of organic 
nitriles from a position of laboratory curiosities to that 
of large tonnage chemicals of commercial importance. 
On the other hand, reactions involving C-C bond 
formation are one of the mainstays in synthetic 
organic chemistry. The use of nitrile function for C-C 
bond formation reactions occupies an important 
position in organic chemistry24-26. 
In light of the above literature and abundance on 
bio-potentials of pyrazolo and pyridine analogues, we 
designed the synthesis of titled compounds having 
carbonitrile as one of the appendages and were 
confident that these frame work would provide the 
important structural motifs for the discovery of new 
antimicrobial agents. In continuation of our research  
on efficient synthesis of biologically active small 
molecules27, we developed one-pot synthesis  
of pyrazolo [3,4-b] pyridine carbonitrile derivatives 
and demonstrated their antimicrobial activity.  
The structure of these compunds was established by  
the IR, 1H NMR spectral data and elemental  
analysis (Scheme I). 
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The required starting material 1-aroyl/ 
aroyloxymethyl-4-arylideno-3-methyl-pyrazolin-5-ones 
was prepared by the following known methods28. A 
mixture of 1-aroyl/aroyloxymethyl-3-methyl-
pyrazolin-5-one, fused sodium acetate and an 
araldehyde in glacial acetic acid was refluxed for 2-3 h. 
The reaction mixture was poured into cold water, 
filtered, dried and recrystallized from methanol to 
furnish the corresponding pyrazolin derivatives. 
 
Antibacterial Activity 
The synthesized pure compounds were sereened for 
their anti bacterial activities adopting standard 
protocols29. The antibacterial activity, of prepared 
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final pure compounds was performed against 
Staphylococcus aureus, Bacillus subtilis, Escherichia 
coli and Klebsiella pneumoniae using Ciprofloxacin 
as positive and DMSO as negative control. Minimum 
inhibitory concentration (MIC) and minimum 
bactericidal concentration (MBC) were determined 
and the activity was reported in g/mL. The nutrient 
broth, which contained logarithmic serially two fold 
diluted amount of test compounds and controls were 
inoculated with approximately 5×105 c.f.u/mL of 
activity dividing bacteria cells. The cultures were 
incubated for 24 h at 37°C and the growth was 
monitored visually and spectrophotometerically. The 
antibacterial results are summarized in Table I, only 
for those compounds which were found active against 
any tested strain of bacteria. It is inferred from Table I 
that compounds 3g, 3i and 3j showed moderate 
activity against gram-positive bacteria S.aureus and 
B.subtilis where as 3n, 3o and 3p were active against 
gram-negative K. pneumoniae ranging from 30 to 50 
g/mL concentration and only one compound 3l was 
found active against E.coli 25 g/mL Concentration 
(Table I). MBC/MIC ratio of all active compounds is 
ranging from 2.0 to 3.3 suggesting these compounds 
are bactericidal not bacteriostatic. Antimicrobial agent 
is considered bacteriostatic when the minimal 
MBC/MIC ratio is greater than or equal to 8 where as 
it is considered bactericidal if MBC/MIC ratio is less 
than or equal to 4. 
 
Fungicidal Activity 
The antifungal activity of the prepared pure 
compounds was performed against Pyricularia oryzae 
Pseudoperonospora cubensis, Sphaerotheca fuliginea 
and phytophthora infestans using Griseofulvin as 
positive and DMSO as negative control. Minimum 
inhibitory concentration (MIC) was determined and 
reported in g/mL. Antifungal activity was carried out 
through disk diffusion method30,31. All fungal cultures 
were routinely maintained on sabouraud dextrose 
(SDA) and incubated at 28°C. The Antifungal 
activities are summarized in Table II, only for those 
compounds which were found active against any of 
these strains of fungi. It is inferred from Table II that 
compounds 3d, 3d, 3e and 3h showed antifungal 
activity against P.oryzae P. cubensis, S.fuliginea and 
P. infestans strain of fungi ranging from 10 to 20 
g/mL in concentration which is comparable to 
Griseofulvin. The structure-activity relationship 
(SAR) of the tested compounds for antifungal as well 
as antibacterial activity can be summarized as follow: 
 
(i) In the series of the substituted pyrazolo [3, 4-b] 
pyridine -5- carbonitrile derivatives has shown 
better antibacterial activity than the o-substituted 
groups. 
(ii) Presence of one or more polar groups in phenyl 
ring with phenoxy moiety is an important 
scaffold for better antibacterial activity.  
(iii) Most of the antibacterial compounds have 
MBC/MIC ratio below 4, it means they are 
bactericidal not bacteriostatic. 
 
Antifungal activity of these compounds was similar 
or even better in some cases as compare to 
Griseofulvin a known antifungal agent. the possible 
meachanism for the antibacterial activity of examined 
Table I — Antibacterial activity of Compounds possess promising biological activity 
Gram-positive bacteria Gram-negative bacteria 
Compd S.aureus B.subtilis E.coli K.pneumonie 
 MIC MBC MIC MBC MIC MBC MIC MBC 
3g 40 100 30 50 n.a. n.a. n.a. n.a. 
3i 30 100 20 50 n.a. n.a. n.a. n.a. 
3j 30 50 40 100 n.a. n.a. n.a. n.a. 
3l n.a. n.a. n.a. n.a. 25 50 n.a. n.a. 
3n n.a. n.a. n.a. n.a. n.a. n.a. 25 50 
3o n.a. n.a. n.a. n.a. n.a. n.a. 25 50 
3p n.a. n.a. n.a. n.a. n.a. n.a. 50 100 
Ciprofloxacin 6.5 12.5 10.0 25 6.25 25 6.25 10.25 
DMSO n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
MIC (g/mL) minimum inhibitory concentration i.e. the lowest concentration of the compound to inhibit growth of bacteria completely, 
MBC (g/mL) minimum bacterial concentration i.e. the lowest concentration of the compound for killing the bacteria completely, 
MBC/MIC ratio are against-S.aureus (3g 2.5, 3i 3.3, 3j 1.6), B. subtilis (3g 1.6, 3i 2.0, 3o 2.0, 3p 2.0), E.coli (3l 2.0) and 
K.pneumoniae aureus (3n 2.0, 3o 2.0, 3p 2.0) n.a. - no activity detected. 
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compounds is not known at the moment and 
investigations are being done to investigate the 
mechanism of antibacterial action, and to synthesize 
more effective compounds. 
 
Experimental Section 
Melting points were recorded in Richerf- 
Thermover instrument and are uncorrected. The IR 
spectra were recorded on Perkin-Elmer RXI 
spectrometer in KBr. 1H and 13C NMR spectra were 
recorded on Bruker 300 and Bruker Avance II 400 
spectrometer using tetra methylsilane (TMS) as an 
internal standard and DMSO-d6/CDCl3 as solvent. 
The micro analytical data were collected on Elemental 
Vario EL III elemental analyzer. All chemicals used 
were purchased from Merck and Fluka Chemicals. 
The homogeneity of compounds was checked by thin 
layer chromatography (TLC) on glass plates coated 
with silica gel G254 (Merck, Mumbai, India) using 
chloroform-methanol (3:1) mixture as mobile phase. 
 
General procedure for synthesis of 1-substituted 
aroyl/substituted aroyloxymethyl-4-substituted aryl 
-3- methyl –6- oxo-6,7-dihydro-1H-pyrazolo [3,4-b] 
pyridine-5-carbonitrile 
A mixture of ethylcyanoacetate (0.01 mol), 1-
aroyl/aroyloxymethyl-4-arylideno-3-methyl pyrazolin 
-5-one (0.01 mo1) and ammonium acetate (0.08 mo1) 
was heated at 150-170°C in an oil bath for 2-3 h. The 
resulting solution was cooled and poured into water. 
The solid product obtained was filtered and washed 
with water, dried and purified by recrystallization 
from ethanol to get crystalline solid products 3a-p. 
3a: Yield 68%. m.p.165°C. IR (KBr): 3200 (NH 
stretching) 3035 (C-H aromatic stretching), 2100  
(C ≡ N Stretching) 1720, 1760 (C= O stretching), 1620 
(C= N stretching) and 1470 cm−1 (C = C Stretching); 
1H NMR (DMSO-d6):  8.0 (s, NH proton), 7.8-6.7 
(m, 9H, H-aromatic), 3.5 (s, 3H, methoxy proton); 13C 
NMR (DMSO-d6):  11.3, 55.2, 92.0, 114.5, 115.5, 
127.7, 129.3, 129.3, 130.5, 132.5, 133.4, 144.2, 165.5, 
168.0, 168.6. 
3b: Yield 65%. m.p 170°C. IR (KBr): 3150 (NH 
stretching), 3025 (C-H aromatic stretching), 2075  
(C ≡ N stretching), 1740, 1700 (C = O stretching), 
1620 (C = N stretching) and 1450 cm−1 (C = C 
stretching); 1H NMR (DMSO-d6):  8.2 (s, NH 
proton), 7.8-6.6 (m. 7H, H-aromatic), 3.7 (s, 6H, 
methoxy proton), 2.7 (s, 3H, methyl proton); 
13C NMR (DMSO -d6):  11.3, 56.2, 92.0, 97.3, 111.6, 
114.5, 115.5, 119.7, 127.7, 129.3, 130.5, 132.5,133.4, 
134.6, 144.2, 149.2, 149.7, 165.5, 168.0, 168.7. 
3c: Yield 70%. m.p.167°C. IR (KBr): 3160 (NH 
stretching), 3010 (C-H aromatic stretching) 2166  
(C ≡ N stretching) 1690, 1720 (C=O stretching) 1610 
(C=N stretching) and 1450 cm−1 (C=C stretching); 
1H NMR (DMSO-d6):  8.0(s, NH proton), 7.7-6.7 
(m, 8H, H-aromatic), 3.7 (s, 3H, methoxy proton), 2.7 
(s, 3H, methyl proton); 13C NMR (DMSO-d6):  11.3, 
55.9, 92.0, 97.7, 111.6, 114.5, 127.5, 128.7, 129.7, 
132.5, 140.0, 144.2, 159.2, 165.7, 168.9. 
3d: Yield 69%. m.p.198°C. IR (KBr): 3140 (NH 
stretching), 3015 (C-H aromatic stretching), 2176  
(C ≡ N stretching), 1680, 1700 (C=O stretching), 
1615 (C=N stretching) and 1470 cm−1 (C=C 
stretching); 1H NMR (DSMO-d6):  8.3 (s, NH 
proton), 7.7-7.2 (m, 8H, H-aromatic), 2.7 (s, NH 
methyl proton); 13C NMR (DMSO-d6):  11.5, 92.0, 
97.7, 115.6, 127.5, 128.1, 128.7, 129.2, 131.3, 133.5, 
138.4, 140.5, 140.6, 144.2, 165.7, 168.5. 
3e: Yield 63%. m.p.178°C. IR (KBr): 3090 (NH 
stretching), 3005 (C-H aromatic stretching), 2210  
(C ≡ N stretching), 1690, 1710 (C=O stretching), 
1620 (C=N stretching) and 1490 cm−1 (C=C 
stretching); 1H NMR (DSMO-d6):  8.2 (s, NH 
proton), 7.6-6.8 (m, 8H, H-aromatic), 3.7 (s, 3H, 
methyl proton); 13C NMR (DMSO-d6):  11.3, 55.9, 
92.0, 97.7, 114.6, 115.9, 127.1, 130.2, 132.3, 132.8, 
135.4, 136.1, 140.6, 141.7, 144.5, 159.9, 165.2, 168.7. 
3f: Yield 67%. m.p.200°C. IR (KBr): 3150 (NH 
stretching), 3010 (C-H aromatic stretching), 
2215(C≡N stretching), 1680, 1715 (C=O stretching), 
1630 (C=N stretching) and 1500 cm−1 (C=C 
stretching); 1H NMR (DMSO-d6):  8.2 (s, NH 
proton), 7.6-6.8 (m, 7H, H-aromatic), 3.7 (s, 3H 
Table II — Antifungal activity of compounds 3b, 3d, 3e and 3h 
Compd Fungal species and MIC (g/mL) 
P.oryzae P.cubensis S.fuliginea P.infestans 
3b 20 16 12 14 
3d 18 14 12 16 
3e 12 10 10 10 
3h 14 12 16 16 
Griseofulvin 20 18 16 18 
DMSO n.a. n.a. n.a. n.a. 
MIC (g/mL), minimum inhibitory concentration i.e. the lowest 
concentration of the compound to inhibit the growth of fungi. 
n.a. – no activity detected. 
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methyl proton); 13C NMR (DMSO-d6):  11.0, 55.9, 
92.0, 97.7, 114.6, 115.9, 127.1, 127.7, 130.2, 132.3, 
132.8, 135.4, 136.1, 140.6, 141.7, 144.5, 159.9,  
165.2, 168.7. 
3g: Yield 72%. m.p.185°C. IR (KBr): 3120 (NH 
stretching), 3015 (C-H aromatic stretching), 2220 
(C≡N stretching), 1690, 1710 (C=O stretching), 1625 
(C=N stretching) and 1495 cm−1 (C=C stretching); 
1H NMR (DMSO-d6):  8.4 (s, NH proton), 7.7-6.7 
(m, 8H, H-aromatic), 5.0 (s, OH proton), 3.7 (s, 3H, 
methoxy proton), 2.8 (s, 3H, methyl proton); 
13C NMR (DMSO-d6):  11.6, 55.9, 92.0, 97.7, 114.0, 
116.0, 127.0, 129.0, 131.0, 132.8, 140.6, 144.7, 159.9, 
165.2, 168.3. 
3h: Yield 64%. m.p.178°C. IR (KBr): 3260 (OH 
stretching): 3150 (NH stretching), 3020 (C-H 
aromatic stretching), 2210 (C≡N stretching), 1685, 
1705 (C=O stretching), 1610 (C=N stretching) and 
1470 cm−1 (C=C stretching); 1H NMR (DMSO-d6):  
7.8 (s, NH, proton), 7.6-6.6 (m, 7H, H- aromatic),  
5.3 (s, OH proton), 3.7 (s, 6H, methoxy proton), 2.7 (s, 
3H, methyl proton); 13C NMR (DMSO-d6):  11.6, 56.2, 
92.0, 98.0, 111.0, 115.2, 116.0, 119.2, 122.0, 131.2, 
133.3, 136.3, 140.6, 144.7, 149.0, 161.8, 165.2, 168.3. 
3i: Yield 66%. m.p.205°C. IR (KBr): 3250 (NH 
stretching), 3025 (C-H aromatic stretching), 2200 
(C≡N stretching), 1680, 1700 (C=O stretching), 1620 
(C=N stretching) and 1490 cm−1 (C=C stretching); 
1H NMR (DMSO-d6):  8.0 (s, NH proton), 7.4-7.2 
(m, 8H, H-aromatic), 2.8 (s, 3H, methyl proton); 13C 
NMR (DMSO-d6):  11.6, 92.0, 97.7, 115.2, 121.2, 
127.7, 128.1, 130.2, 133.5, 136.6, 138.2, 140.3, 144.6, 
154.7, 161.8, 165.2, 168.3. 
3j: Yield 63%. m.p.185°C. IR (KBr): 3190 (NH 
stretching), 3015 (C-H aromatic stretching), 2228 
(C≡N stretching), 1690, 1715 (C=O stretching), 1610 
(C=N stretching) and 1510 cm−1 (C=C stretching); 
1H NMR (DMSO-d6):  8.2 (s, NH proton), 7.4 - 6.6 
(m, 7H, H-aromatic), 3.7 (s, 6H, methoxy proton), 2.8 
(s, 3H, methyl proton); 13C NMR (DMSO-d6):  11.8, 
56.4, 92.0, 97.7, 111.3, 115.2, 115.7, 119.1, 121.2, 
130.5, 133.6, 136.2, 140.5, 144.3, 149.0, 149.8, 154.7, 
165.7, 168.6. 
3k: Yield 65%. m.p.176°C. IR (KBr): 3210 (NH 
stretching), 3028 (C-H aromatic stretching), 2206 
(C≡N stretching), 1680, 1710 (C=O stretching), 1590 
(C=N stretching) and 1490 cm−1 (C=C stretching); 
1H NMR (DMSO-d6):  8.0 (s, NH proton), 7.1-6.7 
(m, 9H, H-aromatic), 5.0 (s, 2H, OCH2 proton), 3.7 (s, 
3H, methoxy proton), 2.7 (s, 3H, methyl proton); 
13C NMR (DMSO-d6):  11.7, 55.8, 71.5, 92.1, 97.9, 
114.3, 114.9, 115.7, 121.1, 127.2, 129.5, 132.6, 140.5, 
144.3, 159.0, 160.8, 168.6, 201.0. 
3l: Yield 64%. m.p.185°C. IR (KBr): 3190 (NH 
stretching), 3030(C-H aromatic stretching), 2200 
(C≡N stretching), 1680, 1710 (C=O stretching), 1590 
(C=N stretching) and 1480 cm−1 (C=C stretching); 
1H NMR (DMSO-d):  8.0 (s, NH proton), 7.1-6.6 (m, 
8H, H-aromatic), 5.1 (s, 2H, OCH2 proton), 3.7 (s, 
6H, methoxy proton), 2.8 (s, 3H, methyl proton); 
13C NMR (DMSO-d6):  11.6, 56.8, 71.6, 92.1, 97.9, 
111.3, 114.9, 115.7, 119.1, 121.2, 129.5, 133.6, 140.5, 
144.3, 149.0, 160.5, 168.3, 201.0. 
3m: Yield 73% m.p.155°C. IR (KBr): 3210 (NH 
stretching), 3020 (C-H aromatic stretching), 3020 (C-
H aromatic stretching), 2190 (C≡N Stretching), 1690, 
1715 (C=O stretching), 1585 (C=N stretching), and 
1475 cm−1 (C=C Stretching); 1H NMR (DMSO-d6);  
8.0 (s, NH proton), 7.3-6.6 (m, 9H, H-aromatic), 5.1 
(s, 2H, OCH2 proton), 2.8 (s, 3H, methyl proton); 
13C NMR (DMSO-d6):  11.6, 71.6, 92.3, 97.7, 114.3, 
115.7, 121.6, 127.5, 128.3, 133.5, 138.4, 140.5, 114.3, 
160.5, 168.3, 201.3. 
3n: Yield 62%. m.p.165°C. IR (KBr): 3190 (NH 
stretching), 3028 (C-H aromatic stretching), 2215 
(C≡N sretching), 1680, 1700 (C=O Stretching), 1590 
(C=N stretching) and 1468 cm−1 (C=C stretching), 
1H NMR (DMSO-d6):  8.2 (s, NH proton), 7.4-6.8 
(m, 8H, H=aromatic), 5.1 (s, 2H, OCH2 proton), 2.8 
(s, 3H, methyl proton); 13C NMR (DMSO-d6):  14.6, 
71.6, 97.3, 98.7, 115.3, 117.3, 126.6, 128.5, 130.3, 
133.8, 138.2, 140.5, 145.3, 156.5, 168.3). 
3o: Yield 67%. m.p.165°C. IR (KBr): 3210 (NH 
stretching), 3015 (C-H aromatic stretching), 2205 
(C≡N stretching), 1690, 1720 (C=O stretching), 1580 
(C=N stretching), and 1465 cm−1 (C=C stretching); 
1H NMR (DMSO-d6):  8.0 (s, NH proton), 7.4-7.0 
(m, 8H, H-aromatic), 5.0 (s, 2H, Methyl proton); 3.8 
(s, 3H, methoxy proton), 2.7 (s, 3H, methyl proton); 
13C NMR (DMSO-d6):  14.5, 55.8, 71.6, 97.3, 98.7, 
114.3, 115.7, 117.2, 126.5, 129.8, 132.4, 140.2, 145.5, 
156.2, 159.0, 168.3. 
3p: Yield 69%. m.p.177°C. IR (KBr): 3205 (NH 
stretching), 3005 (C-H aronatic stretching), 2200 
(C≡N stretching), 1695, 1715 (C=O streteching),1590 
(C=N stretching), and 1468 cm−1 (C=C stretching); 
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1H NMR (DMSO-d6):  8.0 (s, NH proton), 7.4-6.8 
(m, 7H, H-aromatic), 5.0 (s, 2H, OCH2 proton), 3.8 
(s, 6H, methoxy proton), 2.4 (s, 3H, Methyl proton); 
13C NMR (DMSO-d6):  14.3, 56.8, 71.6, 97.2, 98.5, 
108.8, 111.7, 115.4, 117.3, 121.8, 126.4, 130.2, 133.5, 
140.7, 145.5, 149.3, 156.6, 159.0, 168.3. 
 
Conclusion 
In the present investigation, a series of new 
heterocycles have been synthesized and screened for 
their antifungal and antibacterial activity. The activity 
results reveal that the synthesized compounds possess 
moderate to good activity profiles. The insights 
gained in this study will be useful for development of 
newer anti-infective agents. 
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